Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-04-23 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2020年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '2020年度审计报告' which translates to '2020 Annual Audit Report' and contains detailed audit opinions, financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. It includes extensive audit procedures, key audit matters, management and auditor responsibilities, and detailed financial data. The length is substantial (15,000 characters) and the content is the full audit report, not just an announcement or certification. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles, excluding full annual reports. Although it contains financial statements, it is specifically an audit report rather than a full annual report (10-K). Therefore, the correct classification is AR with high confidence.
2021-04-23 Chinese
天士力关于职工代表大会推选第八届监事会职工监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of employee representative supervisors to the company's supervisory board. It includes details about the election process, the term of the new supervisory board, and brief biographies of the elected supervisors. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no indication of a report publication. The content focuses on board/management information, specifically about the supervisory board composition and election results. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a certification, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2021-04-23 Chinese
天士力第七届监事会第14次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 7th Supervisory Board of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals such as the 2020 annual general manager work report, 2020 annual supervisory board work report, 2020 annual financial statements, 2020 profit distribution plan, 2020 annual report, internal control evaluation report, and the 2021 first quarter report. It also discusses supervisory board re-election proposals and other governance matters. The document is not the reports themselves but a formal announcement of the supervisory board's resolutions and approvals related to these reports and proposals. The length is 3485 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filings (RNS) type, which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-04-23 Chinese
天士力第七届董事会第22次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 22nd meeting of the 7th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals related to the 2020 fiscal year, such as the general manager's work report, board work report, audit committee report, financial statements, profit distribution plan, social responsibility report, internal control reports, and other corporate governance matters. It also includes information about board member nominations and other corporate governance decisions. The document repeatedly references that the full reports are published on the Shanghai Stock Exchange website, indicating this document itself is not the full annual report but a summary of board meeting resolutions. This type of document fits the category of Board/Management Information (MANG), as it announces board meeting decisions and management reports rather than providing the full annual report or financial statements themselves.
2021-04-23 Chinese
天士力关于公司2020年度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding the company's 2020 annual main operating data. It contains detailed financial data such as revenue, cost, gross margin, and growth rates segmented by industry, treatment area, product, and region. The document explicitly states that the data is unaudited and is an announcement of key operating data rather than a full financial report. The length is 3356 characters, which is relatively short and consistent with an announcement rather than a full annual report or interim report. There is no indication that this is a full Annual Report (10-K) or Interim Report (IR), nor is it a certification or regulatory filing. It is a disclosure of main operating data for the year 2020, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement of operating data without full financial statements or comprehensive analysis. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-23 Chinese
天士力2021年度预计发生的日常经营性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the expected daily related-party transactions for the year 2021. It includes extensive information about the nature of these transactions, the related parties involved, their financial data, the pricing policies, and the impact on the company. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about related-party transactions that require shareholder approval and disclosure under securities laws. The document is lengthy (over 14,000 characters) and contains detailed transactional and governance information about related-party dealings, which is typical for regulatory filings concerning related-party transactions. It does not fit into categories like M&A, capital updates, or remuneration. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-23 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.